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INTRODUCTION
Carboplatin (cis-diammine [1,1-cyclobutanedicarboxylato]-plat-
inum [II]) is a second generation platinum-containing anti-can-
cer drug used for the treatment of patients with solid tumors 
such as head and neck, lung and ovarian carcinomas (1-3). Al-
though carboplatin has fewer toxic effects than cisplatin, the 
clinical use of carboplatin can be complicated by nephrotoxicity, 
neurotoxicity and ototoxicity (4). Permanent sensorineural hear-
ing loss, particularly at high frequencies, has been reported 
among patients treated with carboplatin (5, 6). 
  Though several studies have sought to determine the underly-
ing mechanism leading to the adverse neurotoxic effects of car-
boplatin, the responsible mechanisms leading to carboplatin 
ototoxicity are not fully understood. However, several lines of 
evidence suggest that damage may be related to an enhanced 
flux of reactive oxygen species (ROS) and reactive nitrogen spe-
cies (RNS) (7-9). Both ROS and RNS, as potential neurotoxins, 
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may be generated by carboplatin and could contribute signifi-
cantly to the damage and death of hair cells and spiral ganglion 
neurons (SGNs). To date, few reports have focused on the pro-
tective effects of antioxidants or nitric oxide synthetase (NOS) 
on carboplatin-induced ototoxicity. 
  N-acetyl-L-cysteine (L-NAC) is a strong antioxidant and in-
duces de novo synthesis of glutathione (GSH). GSH plays a cen-
tral role in the GSH redox cycle, which is important in neutral-
izing free radicals and providing protection from free hyperper-
oxides and lipid peroxides (10). Administration of L-NAC has 
been shown to provide significant protection against oxidative 
stress caused by the depletion of cellular antioxidants and the 
generation of ROS and free radicals in noise-induced hearing 
loss (11). In addition, N-nitro-L-arginine methyl ester (L-NAME), 
an L-arginine analog, non-selectively competes with L-arginine 
and inhibits many different NOS. A previous study reported that 
NO production decreased when the perilymph was perfused 
with L-NAME in a noise-induced hearing loss model (12). Simi-
larly, noise-induced increase in the NO levels in the cochlea was 
significantly attenuated by L-NAME in another study (13).
  In this study, carboplatin induced losses of hair cell and SGN 
were evaluated in cochlear organotypic and dissociated SGN 
cultures. In addition, whether treatment with L-NAC and L-
NAME has a protective effect against carboplatin-induced oto-
toxicity was studied.
MATERIALS AND METHODS
Organotypic cultures 
Cochleae were dissected from postnatal day 5 (P5) mouse pups 
under the microscope. The skull was opened and the temporal 
bones were harvested. The cochleae containing the middle turn 
of the organ of Corti were removed from the temporal bone and 
cultured for 24 hours in Dulbecco’s Modified Eagle Medium 
(DMEM; Invitrogen, Carlsbad, CA, USA) containing 10% fetal 
bovine serum (FBS; Invitrogen). These tissues were cultured in 
collagen-coated Transwells (Corning Life Science, Corning, NY, 
USA). During the initial 24-hour culture, the cochleae of the L-
NAC (Sigma, St. Louis, MO, USA) and L-NAME (Sigma) groups 
were placed in DMEM containing 10% FBS added with L-NAC 
(10 mM) and L-NAME (100 mM), respectively. Thereafter, the 
cochleae were placed in different media according to the group 
as described below. The cochleae from the control group were 
placed in DMEM containing 10% FBS for additional 48 hours, 
while the cochleae from the carboplatin , L-NAC and L-NAME 
groups were placed in media with carboplatin added (100 mg/
mL), carboplatin plus L-NAC (10 mM), and carboplatin plus L-
NAME (100 mM), respectively, for 48 hours. 
Dissociated SGNs cultures 
Dissociated SGNs cultures were prepared from P5 mice cochle-
ae using a procedure described previously (14). Cochleae were 
aseptically removed from the temporal bone and placed in ice-
cold phosphate buffered saline (PBS). The bony cochlear capsule 
and spiral ligament were removed. The organ of Corti was then 
removed, transecting the outer radial fibers, leaving the SGNs 
within the modiolus. Modiolar bone was removed and sur-
rounding connective tissue was incompletely removed. Ganglia 
were collected in ice-cold Hank’s balanced salt solution (HBSS).
  Enzymatic dissociation was performed in Ca
2+/Mg
2+-free 
HBSS with 0.1% collagenase, 0.1% trypsin, and 0.01% DNase 
I (Boehringer Mannheim, Indianapolis, IN, USA) in a gently 
shaking 37°C water bath for 30 minutes. FBS was added to 
10% to inhibit enzymatic activity, followed by three washes in 
serum-free DMEM. The ganglia were dissociated mechanically 
using two fire-polished reduced orifice glass pipettes. The second 
pipette used in this procedure was considerably narrower than 
the first. The ganglia were gently triturated about 15 times with 
each pipette and filtered through a nylon mesh (Nitex, 15 mm, 
Tetko Inc., Elmsford, NY, USA). 
  Dissociated spiral ganglion cells were plated in 8-well slides 
(Marienfeld, Bad Mergentheim, Germany) that had been treated 
with 0.01% polyornithin (Sigma) for one hour at room temper-
ature, followed by laminin (20 μg/mL; Sigma) overnight at 4°C. 
The dissociated cells were cultured in 100 μL of culture media 
(N2, 0.5×B27 and insulin supplemented high-glucose DMEM) 
at 37°C in a 5% CO2 incubator. The controls were treated with 
50 ng/mL BDNF (Invitrogen) and 50 ng/mL NT-3 (Invitrogen). 
After an initial 24-hour culture, the cells were exposed to carbo-
platin (50 mg/mL) for an additional 48 hours. The cells in the 
antioxidant-treatment groups were exposed to L-NAC (100 
mM), L-NAME (100 mM) and L-NAC plus L-NAME during 
both the initial 24-hours culture period and the additional 
48-hours of carboplatin treatment. All in vitro experiments were 
repeated three times and similar results were obtained each 
time.
Immunofluorescence staining
The cultured tissues were fixed in 4% paraformaldehyde and 
washed three times with PBS. The specimens were then reacted 
with 0.1% Triton X-100 for 15 minutes at room temperature. 
After washing, the specimens were reacted with a blocking se-
rum (normal goat serum) for one hour and incubated overnight 
with a 1:400 dilution of the anti-NF 200 antibody (Sigma). The 
specimens were then washed and incubated with a 1:50 dilution 
of rhodamine-conjugated IgG (Zymed, South San Francisco, CA, 
USA) for 30 minutes at 37°C. Then, the tissues were incubated 
with FITC-labeled phalloidin (0.1 mg/mL) for 20 minutes at 
room temperature. 
  The staining procedures of dissociated SGN cultures were per-
formed in the same manner as the tissues, except using different 
secondary conjugated fluorescent dye (FITC-conjugated IgG; 
Zymed). For nuclear staining, Hoecsht 33258 (1 mg/mL; Invit-Moon IJ et al.: N-acetylcysteine and N-Nitroarginine Methyl Ester Prevents Carboplatin-Induced Ototoxicity    13
rogen) was used. The specimens were finally washed and mount-
ed for microscopic examination. The specimens were examined 
under a confocal and fluorescence microscope. The criteria used 
to determine neuronal viability were 1) NF-200 positivity, with 
a visible nucleus, and 2) absence of nuclear pyknosis.
Statistical analysis
Statistical analysis was performed to compare the number of 
hair cells in the animals after treatment with carboplatin, using 
the Wilcoxon rank sum test with the SPSS ver. 12.0 (SPSS Inc, 
Chicago, IL, USA). P-values of <0.05 were considered to be sta-
tistically significant.
RESULTS
Carboplatin induced ototoxicity and its protection in cochlear 
organotypic cultures
Fig. 1A shows the typical arrangement of inner hair cells (IHCs) 
and outer hair cells (OHCs) in untreated 72 hour cochlear or-
ganotypic cultures. The neurites from the SGN somata were well 
visualized. Although the structure of the organ of Corti was 
maintained in the carboplatin-treated group, most of the stereo-
cilia bundles of OHCs were slightly destroyed (Fig. 1B). A few of 
the OHCs in the third row were missing while a considerable 
number of them were present in the first and second rows. Ste-
reocilia in IHCs also showed minimal deformations. In addition, 
some of the neurite connections between hair cells and SGNs, 
in the carboplatin-treated group, were missing or extremely thin 
and difficult to discern compared to those in the control group. 
However, these destructive changes of the hair cells in the organ 
of Corti were not definite in both groups pre-treated with L-NAC 
and L-NAME (Fig. 1C, D). The damaged neurite connections af-
ter carboplatin treatment were not recovered by addition of L-
NAC or L-NAME. 
  Fig. 2 shows the mean number of IHCs and OHCs in the mid-
dle turn of the cochleae in each group. No differences were ob-
served among all experimental groups regarding the number of 
IHCs (Fig. 2A). The number of OHCs in the carboplatin-treated 
group was significantly lower than in the control group (P=0.025). 
However, slight differences were noted between the number of 
OHCs in the carboplatin-treated group and those in L-NAME/
L-NAC treated groups, even though the differences did not reach 
statistical significance (Fig. 2B). 
Carboplatin cytotoxicity and its protection in dissociated SGNs 
cultures
SGNs were stained with NF-200, a neuronal specific marker, and 
Fig. 1. Confocal microscopic photomicrographs of cochlear organotypic cultures stained with FITC-conjugated phalloidin (green) and NF-200 
(red). (A) Control showing a typical arrangement of three rows of outer hair cells, and single row of inner hair cells. (B) Cochlear cultures treat-
ed for 48 hours with carboplatin at a concentration of 100 mg/mL. (C) Cochlear cultures treated for 48 hours with 100 μg/mL carboplatin plus 
100 μM N-nitro-L-arginine methyl ester. (D) Cochlear cultures treated for 48 hours with 100 μg/mL carboplatin plus 10 mM N-acetyl-L-cysteine. 
Scale bar represents 10 μm.
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neuronal survival was determined by counting NF-200-positive 
cells as described in the Materials and Methods section. As 
shown in Fig. 3, the dissociated SGNs treated with carboplatin 
showed cytotoxicity (Fig. 3B) compared to the untreated group 
(Fig. 3A). As shown in Fig. 3C and D, L-NAME and L-NAC pro-
moted survival compared to the control group. In addition, the 
cytotoxicity of the SGNs in the carboplatin-treated group was 
partially prevented when L-NAME or L-NAC were added prior 
to carboplatin administration; however, neurite outgrowth was 
not affected by the addition of L-NAME or L-NAC (Fig. 3E, F). 
  Neuronal viability in the experimental conditions is expressed 
as the percentage of the average number of NF-200-positive 
cells in triplicate parallel cultures in the control group (Fig. 4). 
The number of surviving SGNs, in the groups treated with ei-
ther L-NAME or L-NAC alone, was significantly higher than in 
the control group. Administration of carboplatin significantly re-
duced the mean number of surviving SGNs in dissociated cul-
Fig. 3. Fluorescence microscopic photographs of dissociated spiral ganglion neuron cultures stained with NF-200 (green) and Hoechst (blue) 
after 72 hours of culture. (A) Untreated control, (B) 50 mg/mL carboplatin only, (C) 100 mM N-nitro-L-arginine methyl ester (L-NAME) only, (D) 
100 mM N-acetyl-L-cysteine (L-NAC) only, (E) 50 mg/mL carboplatin+100 mM L-NAME, (F) 50 mg/mL carboplatin+100 mM L-NAC (×400).
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Fig. 2. Histogram shows mean number of outer hair cells (OHCs), 
per (A) and inner hair cells (IHCs) (B) per 0.2 mm length of the co-
chlea. Asterisk indicates that the carboplatin-treated group shows a 
statistically significant decrease in the OHC number compared to 
the control group. L-NAME: N-nitro-L-arginine methyl ester; L-NAC: 
N-acetyl-L-cysteine.
I
H
C
s
/
0
.
2
 
m
m
Control
Carboplatin
Carboplatin + L-NAME
Carboplatin + L-NAC
30
20
10
0
O
H
C
s
/
0
.
2
 
m
m
Control
Carboplatin
Carboplatin + L-NAME
Carboplatin + L-NAC
90
80
70
60
50
40
30
20
10
0
*
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ganglion neuron (SGN) cultures for 72 hours. The survival of SGNs 
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trol group. L-NAME: N-nitro-L-arginine methyl ester; L-NAC: N-ace-
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tures compared to the control group. Addition of L-NAME or L-
NAC appeared to rescue SGNs from carboplatin-induced death; 
these differences were statistically significant. There was no sig-
nificant difference in the mean number of surviving SGNs be-
tween the groups treated with L-NAME and L-NAC. Moreover, 
the combination of L-NAME plus L-NAC did not show an addi-
tive effect on neuronal survival compared to treatment with ei-
ther agent alone.
DISCUSSION
Carboplatin is currently used in oncology clinics for the treat-
ment of a variety of cancers. It is considered an alternative anti-
cancer drug, and usually recommended for chemotherapy in pa-
tients with ovarian cancer, lung cancer and head and neck can-
cer. High dose carboplatin has been shown to cause hearing loss 
as a side effect in cancer patients (15). Therefore, to clarify the 
mechanism of carboplatin-induced ototoxicity, many studies 
have been performed with various animal models. 
  The ototoxic mechanism associated with carboplatin treatment 
remains unknown. However, the available evidence implies that 
carboplatin-induced ototoxicity results from enhanced flux of 
free radicals and depletion of antioxidants in the cochlea (7, 9). 
In addition, a recent study revealed that cytotoxicity induced by 
cisplatin, which is an analogue of carboplatin, is associated with 
an increase in ROS production (16). ROS has known to play a 
major role in loss of outer hair cells and spiral ganglia of mouse 
after cisplatin administration (17). Furthermore, NO is a simple 
inorganic radical that is produced by different isoforms of a nic-
otinamide adenine dinucleotide phosphate hydrogen (NADPH)-
dependent enzyme, NOS, and known to be associated with co-
chlear pathology in a variety of conditions (12, 18, 19). 
  An earlier study showed that carboplatin significantly in-
creased NO levels and decreased GSH peroxidase levels in the 
cochleae of rats (7). In addition, hearing thresholds were changed 
by NO elevation and GSH depletion in the cochleae of rats treat-
ed with carboplatin. A recent study also reported a significant 
role of NO in carboplatin-induced ototoxicity (9). Cochlear NO 
levels were significantly higher in rats treated with carboplatin 
than in the controls. Moreover, administration of L-NAC prior 
to carboplatin treatment decreased NO levels in the cochleae 
and had a protective effect against carboplatin-induced ototoxic-
ity. Furthermore, similar results were observed in mouse that 
apoptosis triggered by inducible NOS mediates the ototoxicity 
induced by cisplatin, which has similar characteristics of carbo-
platin (20). The results of this study are consistent with the find-
ings of previous studies. 
  In the present study, we demonstrated that carboplatin in-
duced significant OHC damage, especially in the third row, in 
cochlear organotypic cultures. By contrast, IHC loss was not 
definite; there was no difference in the number of IHCs between 
the control and treated groups. However, minimal deformation 
of the stereocilia in the IHCs was observed. Cochlear organo-
typic cultures were obtained from P5 mice; therefore, this predi-
lection of injury in the OHCs may be a characteristic of these 
newborn mice. In cochlear organotypic cultures, L-NAME or L-
NAC administration did not have a statistically significant pro-
tective effect on hair cells. However, there was an increasing 
trend of survival of the OHCs after administration of L-NAME 
or L-NAC; however, the changes did not reach statistical signifi-
cance. 
  In order to clarify the effect of carboplatin on SGNs, carbopl-
atin was added to dissociated SGN cultures. The mean number 
of surviving SGNs, in the groups with L-NAME or L-NAC with-
out carboplatin treatment, was significantly higher than in the 
control group. These results imply that L-NAME or L-NAC them-
selves are effective for the survival of SGNs in dissociated cul-
tures. These compounds may attenuate the toxic effects of ROS 
or RNS naturally generated in the normal culture environment. 
Free radicals and NO may be responsible for spontaneous SGN 
death in the culture medium. 
  In this study, carboplatin treatment significantly reduced the 
mean number of surviving SGNs in dissociated cultures. A pre-
vious study also demonstrated a distinct loss of SGNs after car-
boplatin administration in a chinchilla model (21). However, in 
the previous study, the SGN population decreased progressively 
from 2 to 12 weeks after IHC loss. Therefore, they postulated 
that selective damage to the IHCs caused SGN loss. By contrast, 
the results of this study demonstrated direct cytotoxicity to the 
SGNs in dissociated cultures. Interspecies differences to the sus-
ceptibility to carboplatin might explain the difference between 
these two studies. 
  Administration of carboplatin might have an adverse effect on 
neurite growth from the SGN somata in dissociated cultures, as 
observed in this study. This finding is consistent with the findings 
of a previous study that reported the inhibition of neurite out-
growth in organotypic cultures of rat dorsal root ganglia treated 
with carboplatin (22). However, the mechanism responsible for 
this inhibition is not fully understood. Administration of L-NAME 
or L-NAC did not attenuate the toxic effects of carboplatin on 
neurites in this study. The results of a recent study showed that 
the physiological level of the ROS was critical for maintaining 
and controlling neurite outgrowth in the neuronal cells (23). 
Moreover, it has been reported that NO plays a critical role in 
neurite outgrowth of neuroblastoma cells and that the addition 
of L-NAME inhibits neurite outgrowth of neuroblastoma cells 
(24). However, L-NAME or L-NAC alone did not affect the neu-
rite length of damaged SGNs by carboplatin while they promot-
ed the survival of SGNs in this study. Therefore, ROS and RNS 
may not be involved in the inhibition of neurite outgrowth of 
SGNs in mice exposed to carboplatin. 
  In addition, pre-administration of L-NAME and L-NAC sig-
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ated SGN cultures; however, they did not show an additive ef-
fect. The direct toxicity of NO is known to be modest but is en-
hanced by reactions with superoxide to form peroxynitrite, 
which has direct cytotoxicity (25). Thus, NO and the related 
ROS may cause cell death in an additive manner. However, 
combination of L-NAME and L-NAC did not have an additive 
effect on neuronal survival compared to treatment with either 
agent alone, in this study. It is postulated that the mechanism, 
related to ROS and RNS, might share an overlapping pathway 
leading to damage and death in carboplatin-induced cytotoxicity 
in dissociated SGN cultures. 
  Carboplatin-induced ototoxicity has been demonstrated in a 
variety of experimental animals (9, 26-29). A number of previ-
ous studies showed that ototoxicity to carboplatin varies consid-
erably across different species. IHCs and type-I spiral ganglion 
neurons are preferentially destroyed in carboplatin-treated chin-
chillas, while OHCs are spared (26). Guinea pigs are relatively 
resistant to the ototoxic effects of carboplatin. However, when 
ototoxicity develops after treatment with carboplatin in guinea 
pigs, selective degeneration of the OHCs near the base of the 
cochlea occurs and the IHCs remain intact (29, 30). Although 
many animal studies have been performed to elucidate the 
mechanism of carboplatin-induced ototoxicity, there have been 
few prior reports using mice. Therefore, the feasibility of a mouse 
model for carboplatin-induced ototoxicity was examined in this 
study (data not shown). 
  Fifteen 5-6 week C57BL/6J mice were used in this study. Un-
expectedly, 12 (80%) out of 15 mice treated with carboplatin 
(120 mg/kg, intraperitoneal injection) died within 2 weeks, and 
the remaining three mice were included in the analysis. This un-
anticipated result may be due to different individual susceptibili-
ties to carboplatin among the mice. It is postulated that nephro-
toxicity may precede ototoxicity in a mouse model. The byprod-
uct of carboplatin, platinum-ammine-DNA adduct, accumulates 
in the kidney and induces renal tubular damage (31). This accu-
mulation of byproducts might be responsible for the death of 
the mice in this study. All three surviving mice showed signifi-
cant cochlear damage, including partial-to-total loss of OHCs 
and minimal deformation of IHCs, which are consistent with the 
results from the organotypic cultures in this study. Although sig-
nificant damage was identified in some mice in this study, a high 
proportion of death and different individual susceptibilities sug-
gest that a mouse model is not suitable for experiments studying 
carboplatin-induced ototoxicity. 
  In summary, carboplatin is toxic to cochlear hair cells, SGNs 
and neurites between hair cells and SGNs in organotypic and 
dissociated cultures from mice. In addition, administration of L-
NAME and/or L-NAC attenuated cytotoxicity of carboplatin to 
SGNs in dissociated SGN cultures. Therefore, reactive oxygen 
radicals and NO may be responsible for certain damage to the 
cochlea caused by carboplatin treatment.
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